(Q34147687)

English

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

gastroenterology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

corrigendum / erratum

Erratum: Corrigendum: The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Respo

1 reference

10.1038/AJG.2010.484

12 July 2019

http://api.crossref.org/works?select=update-to&filter=doi:10.1038/AJG.2010.484

William Jeffery Sandborn

25

object named as

William J Sandborn

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Brian G. Feagan

24

object named as

Brian Feagan

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jean-Frédéric Colombel

26

object named as

Jean Frédéric Colombel

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Walter Reinisch

19

object named as

Walter Reinisch

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Remo Panaccione

2

object named as

Remo Panaccione

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

13

object named as

Bruce Sands

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Stephen B Hanauer

7

object named as

Stephen B Hanauer

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Séverine Vermeire

4

object named as

Severine Vermeire

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Stefan Schreiber

20

object named as

Stefan Schreiber

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Peter D R Higgins

3

object named as

Peter D R Higgins

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

6

object named as

Yehuda Chowers

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

17

object named as

Marc Lémann

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

21

object named as

Corey Siegel

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1

object named as

Geert R D'Haens

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

18

object named as

Scott Plevy

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5

object named as

Miquel Gassull

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Hans H Herfarth

8

object named as

Hans Herfarth

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Robert Löfberg

11

object named as

Robert Löfberg

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

16

object named as

Bret Lashner

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Stephan R. Targan

22

object named as

Stephen Targan

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Michael A. Kamm

10

object named as

Michael Kamm

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Daan W Hommes

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A Quary

12

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

A Sood

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

G Watermeyer

15

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

M Watanabe

23

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Simon Travis

27

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

2 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

106

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

199-212; quiz 213

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab maintenance therapy for fistulizing Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Adalimumab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

European evidence-based Consensus on the management of ulcerative colitis: Current management

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Frequency of glucocorticoid resistance and dependency in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Mortality and causes of death in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Genetic risk profiling and prediction of disease course in Crohn's disease patients

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Role of genetics in prediction of disease course and response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab improves quality of life in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Predictors of response to infliximab in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Predictors of early response to infliximab in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Long-term outcome after infliximab for refractory ulcerative colitis

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Laboratory markers in IBD: useful, magic, or unnecessary toys?

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

The efficacy and safety of a third anti-TNF monoclonal antibody in Crohnâ s disease after failure of two other anti-TNF antibodies

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Durability of infliximab in Crohn's disease: a single-center experience

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab prevents Crohn's disease recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.392

21 January 2018

Identifiers

10.1038/AJG.2010.392

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34147687&oldid=2130406321"